Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 10/19/2025

Cholesterol Lowering and Cognitive Function

Introduction to Cholesterol Lowering

  • The American College of Cardiology recommends that lowering cholesterol does not increase the risk of developing dementia and should not be avoided due to cognitive concerns, based on the highest quality evidence from multiple major medical societies and randomized controlled trials 1, 2, 3, 4

Evidence from Randomized Controlled Trials

  • Three major randomized trials comparing statins to placebo performed specific cognitive testing and found no differences in cognitive function between groups, as stated by the American Diabetes Association 2, 3, 4
  • The EBBINGHAUS sub-study of FOURIER specifically evaluated evolocumab and found no difference in cognitive function at 19 months, with the primary endpoint of spatial working memory showing noninferiority, according to the European Heart Journal 5, 6, 7, 8
  • Studies adding ezetimibe or PCSK9 inhibitors to statin therapy showed no cognitive decline, even among patients achieving very low LDL cholesterol levels, as reported by the American Diabetes Association 2, 3, 4

Guideline Consensus

  • The 2013 ACC/AHA Cholesterol Guideline states that RCT evidence does not support an adverse effect of statins on cognitive changes or risk of dementia, as stated by the American College of Cardiology 1
  • The 2019 and 2023 ADA Standards of Care conclude that concerns about statins causing cognitive dysfunction or dementia are not supported by evidence and should not deter their use in high-risk individuals, according to the American Diabetes Association 2, 3, 4

Understanding the Biological Context

  • Brain cholesterol regulation depends primarily on local de novo synthesis within the brain rather than circulating plasma cholesterol levels, as explained by the European Heart Journal 5, 6, 8
  • This explains why lowering blood cholesterol does not impair brain function, as the brain maintains its own cholesterol homeostasis independently, according to the European Heart Journal 5, 6, 8

Addressing Reported Neurocognitive Events

  • The FDA's systematic review of postmarketing surveillance databases, randomized trials, and observational studies found no adverse effect of statins on cognition, as reported by the American Diabetes Association 2, 3, 4
  • The 2024 ADA Standards note that control of blood pressure and cholesterol lowering with statins are associated with reduced risk of incident dementia in older adults, according to the American Diabetes Association 9

Clinical Management Algorithm

  • Reassure patients that high-quality randomized trial evidence shows no increased dementia risk from cholesterol lowering, as stated by the American College of Cardiology and the American Diabetes Association 1, 2, 3, 4
  • Emphasize that cardiovascular benefits far outweigh any theoretical cognitive concerns, according to the American College of Cardiology and the American Diabetes Association 1, 2, 3

Important Caveats

  • However, these limitations do not justify withholding proven cardiovascular therapy based on unsubstantiated cognitive concerns, as reported by the American Diabetes Association 2, 3, 4

Statin Use in Patients with Dementia

Introduction to Statin Guidelines

  • The American Diabetes Association, American College of Cardiology, and European Society of Cardiology recommend statins for cardiovascular risk reduction in patients with established atherosclerotic disease, regardless of dementia status 10, 11

Secondary Prevention

  • Statins are strongly recommended in patients with prior MI, ACS, stroke, or peripheral artery disease to prevent cardiovascular events, even in those with dementia 10, 12
  • The European guidelines state that ischemic cerebrovascular disease merits the same lipid treatment as coronary disease 10
  • This recommendation is based on proven mortality reduction in high-quality randomized trials 12, 13

Primary Prevention

  • Statins should be used according to standard cardiovascular risk assessment 10, 11

Cognitive Safety

  • Multiple lines of high-quality evidence demonstrate that statins do not cause cognitive decline or dementia 11
  • The FDA's systematic review found no adverse cognitive effects 11

Clinical Decision Making

  • The American College of Cardiology recommends continuing or starting statins in patients with established atherosclerotic CVD, regardless of dementia status 10, 12
  • The European Society of Cardiology suggests considering patient life expectancy and goals of care when making decisions about statin use 10
  • For every 255 patients treated with statins for 4 years, 5.4 cardiovascular events are prevented 11
  • Statins should be used at appropriate intensity based on cardiovascular indication, not dementia status 10, 13

REFERENCES